Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

--Alimera Sciences, Inc., a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases ...

ATLANTA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and ...

The Iluvien brand has a potential global market worth $2 billion, Myers said. To date, Iluvien has been implanted in more than 1,500 eyes in the European Union, Myers said.

ILUVIEN revenues should pick up by the end of the year. DME is a chronic disease and there is a desperate need for a sustained release treatment and ILUVIEN fills that need very well.

A single ILUVIEN implant significantly delayed recurrence and reduced uveitis symptoms upon recurrence compared to active control arm Recently approved in Europe, ILUVIEN is expected to launch in ...

An expert consensus was recently published by Kolomeyer and colleagues to gain insight into current understanding of the role of inflammation in diabetic macular edema pathophysiology and the ...

Iluvien was approved by the Food and Drug Administration back in 2014 for the treatment of DME in patients who were previously treated with corticosteroids without a clinically significant rise in ...